The GLP is committed to full transparency. Download and review our 2019 Annual Report

Evidence matters in genomic medicine: Cancer genomic tests

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

In a previous blog, CDC’s Office of Public Health Genomics announced a list of health-related genomic tests and applications, stratified into three tiers according to the availability of scientific evidence and evidence-based recommendations as a result of systematic reviewsExternal Web Site Icon.  The list is intended to promote information exchange and dialogue among researchers, providers, policy makers, and the public. We have updated the list to include tests that have been discussed in a recent article by the National Comprehensive Cancer Network (NCCN)External Web Site Icon. For these tests, we have considered NCCN recommendations and other evidence-based reviews, reports or assessments from Blue Cross Blue Shield Association Technical Evaluation Center (TEC)External Web Site Icon and guidelines from the National Institute for Health and Clinical ExcellenceExternal Web Site Icon in the placement of individual tests within the OPHG tier list.

View the original article here: Evidence matters in genomic medicine: Cancer genomic tests

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend